재귀 제약, Inc.
| Security | RXRX / Recursion Pharmaceuticals, Inc. |
| Insider | Najat Khan |
This page shows the track record and history of Khan Najat
insider trades in Recursion Pharmaceuticals, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.
It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). This does not mean
it is illegal for them to make any
trades in their own companies. However, they must report all trades to the SEC via a Form 4.
Insider Purchases - Short Term Profit Analysis
In this section, we analyze the profitability of every unplanned, open-market insider purchase made by Najat Khan in RXRX / Recursion Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Max |
Price at Max |
Max Profit ($) |
Max Return (%) |
|---|---|---|---|---|---|---|---|
| There are no known unplanned open-market trades for this insider |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Sales - Short Term Loss Analysis
In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made by Najat Khan in RXRX / Recursion Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.
The following table shows the most recent open market purchases that were not part of an automatic trading plan.
| Trade Date | Reported Shares |
Reported Price |
Adjusted Shares |
Adjusted Price |
Cost Basis | Days to Min |
Price at Min |
Max Loss Avoided ($) |
Max Loss Avoided (%) |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-18 | 36,599 | 5.5240 | 36,599 | 5.5240 | 202,173 | 224 | 2.8400 | -98,231 | -48.59 |
Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.
Insider Transaction History
| File Date |
Trade Date |
Form | Insider | Ticker | Security Title | Code | Direct | Exercise Price |
Unit Price |
Units Changed |
Value Changed (1K) |
Remaining Options |
Remaining Shares |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-05 | 2026-06-05 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 3.5806 | -23,588 | -84 | 2,175,796 | ||||
| 2026-05-19 | 2026-05-15 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 3.0400 | -62,701 | -191 | 2,199,384 | ||||
| 2026-03-11 | 2026-03-09 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 3.3451 | -28,298 | -95 | 2,262,085 | ||||
| 2026-02-19 | 2026-02-17 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 3.4900 | -14,280 | -50 | 2,290,383 | ||||
| 2026-02-10 | 2026-02-06 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 3.9800 | -10,364 | -41 | 2,304,663 | ||||
| 2026-02-10 | 2026-02-06 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 30,346 | 2,315,027 | ||||||
| 2026-02-10 | 2026-02-06 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 1,673,546 | 2,284,681 | ||||||
| 2025-12-29 | 2025-12-22 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 4.4098 | -124,403 | -549 | 611,135 | ||||
| 2025-11-19 | 2025-11-17 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 4.1400 | -17,584 | -73 | 735,538 | ||||
| 2025-11-06 | 2025-11-05 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 84,925 | 753,122 | ||||||
| 2025-08-19 | 2025-08-18 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 5.5240 | -36,599 | -202 | 668,197 | ||||
| 2025-08-19 | 2025-08-15 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 5.6400 | -3,789 | -21 | 704,796 | ||||
| 2025-05-19 | 2025-05-15 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 4.2500 | -3,796 | -16 | 708,585 | ||||
| 2025-02-05 | 2025-02-03 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 7.2500 | -2,753 | -20 | 712,381 | ||||
| 2025-02-05 | 2025-02-03 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 8,049 | 715,134 | ||||||
| 2025-02-05 | 2025-02-03 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 210,113 | 707,085 | ||||||
| 2024-08-05 | 2024-08-01 | 4 | Khan Najat | RXRX | Class A Common Stock | D | 496,972 | 496,972 |
P
공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매입
S
공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매각
A
자사로부터 유가증권(옵션 등)을 보조, 지급 또는 기타 취득
C
파생상품 전환
D
자사에게 유가증권을 매각 또는 양도
F
기업으로부터 인도 받은 유가증권의 일부를 사용한 행사 가격 또는 조세 채무의 지급
G
내부자에 의한 또는 내부자에게 증권 증여
K
지분스왑 및 유사 위험 회피거래
M
자사로부터 인도 받은 파생증권(옵션 등)의 행사 또는 전환
V
보고서 양식 4에 자진 신고된 거래
J
기타 (거래 내용을 설명하는 각주와 동반)
